Biosimilars and Biologics in Medicare Part D: MedP…

Biosimilars and Biologics in Medicare Part D: MedPAC briefing deck Via @medicarepayment #pharma #biotech goo.gl/awzqFL

Drug Pricing Reform: Understanding Indication Spec…

Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals #pharma #biotech #drugs… twitter.com/i/web/status/7…

Biologics and Biosimilars: Backgrounder on FDA reg…

Biologics and Biosimilars: Backgrounder on FDA regulatory issues, price comparisons, approvals goo.gl/qG2Twj #biotech #pharma

Drug companies offer money back guarantees for hig…

Drug companies offer money back guarantees for high-cost, cutting-edge therapies #pharma #biotech flip.it/oLzNSO

Drug Development, Drug Pricing Dynamics, Supply Ch…

Drug Development, Drug Pricing Dynamics, Supply Chain: Overview by MedPAC medpac.gov/documents/fact… #pharma #drugs #biotech #pharmacy

Medicare Prescription Drug Spending: Overview by M…

Medicare Prescription Drug Spending: Overview by MedPAC. medpac.gov/documents/fact… #pharma #drugs #biotech

Medicare, Oncology, and Drugs: MedPAC deck on Part…

Medicare, Oncology, and Drugs: MedPAC deck on Part B payment reforms. goo.gl/PJQGra #cancer #biotech #pharma

Health Insurers’ Perspectives on the Orphan Drug P…

Health Insurers’ Perspectives on the Orphan Drug Pipeline. goo.gl/c7v0HQ #FDA #Pharma #Drugs #Biotech

Economics of Biosimilars: Biologic drug market mak…

Economics of Biosimilars: Biologic drug market makes entry attractive but very risky. ahdbonline.com/issues/2013/se… #FDA #pharma #biotech

RT @AlecGaffney: Morning! HUGE edition of Regulato…

RT @AlecGaffney: Morning! HUGE edition of Regulatory Recon, with all the #Pharma, #MedDevice, #Biotech and #FDA news you can handle: ow.ly/qH8ZN